SK10497A3 - Use of a progesterone antagonist and of a gestagen for the treatment of endometriosis or leiomyomata uteri - Google Patents

Use of a progesterone antagonist and of a gestagen for the treatment of endometriosis or leiomyomata uteri Download PDF

Info

Publication number
SK10497A3
SK10497A3 SK104-97A SK10497A SK10497A3 SK 10497 A3 SK10497 A3 SK 10497A3 SK 10497 A SK10497 A SK 10497A SK 10497 A3 SK10497 A3 SK 10497A3
Authority
SK
Slovakia
Prior art keywords
hydroxy
gestagen
product according
competitive progesterone
estradien
Prior art date
Application number
SK104-97A
Other languages
English (en)
Slovak (sk)
Inventor
Klaus Stockemann
Kristof Chwalisz
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of SK10497A3 publication Critical patent/SK10497A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK104-97A 1994-07-27 1995-07-27 Use of a progesterone antagonist and of a gestagen for the treatment of endometriosis or leiomyomata uteri SK10497A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4426601A DE4426601A1 (de) 1994-07-27 1994-07-27 Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
PCT/EP1995/002998 WO1996003130A1 (de) 1994-07-27 1995-07-27 Progesteronantagonist und gestagen zur behandlung der endometriose und leiomyomata uteri

Publications (1)

Publication Number Publication Date
SK10497A3 true SK10497A3 (en) 1997-08-06

Family

ID=6524269

Family Applications (1)

Application Number Title Priority Date Filing Date
SK104-97A SK10497A3 (en) 1994-07-27 1995-07-27 Use of a progesterone antagonist and of a gestagen for the treatment of endometriosis or leiomyomata uteri

Country Status (22)

Country Link
US (1) US6043234A (ko)
EP (1) EP0772441B1 (ko)
JP (1) JPH10502092A (ko)
KR (1) KR100365879B1 (ko)
CN (1) CN1124848C (ko)
AT (1) ATE213417T1 (ko)
AU (1) AU705618B2 (ko)
CA (1) CA2195425C (ko)
CZ (1) CZ292177B6 (ko)
DE (2) DE4426601A1 (ko)
DK (1) DK0772441T3 (ko)
ES (1) ES2172592T3 (ko)
FI (1) FI970260A (ko)
HU (1) HU226453B1 (ko)
IS (1) IS4407A (ko)
MX (1) MX9700309A (ko)
NO (1) NO970309L (ko)
NZ (1) NZ291417A (ko)
PL (1) PL318264A1 (ko)
PT (1) PT772441E (ko)
SK (1) SK10497A3 (ko)
WO (1) WO1996003130A1 (ko)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19531936A1 (de) * 1995-08-17 1997-02-20 Schering Ag Kombinationspräparat zur Kontrazeption, Kits diese enthaltend und eine Methode diese verwendend
HUP0100542A3 (en) 1997-11-14 2001-10-29 Akzo Nobel Nv Progestogen and antiprogestogen containing kit, process for its preparation and use of the compounds for the preparation of contraseptives
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
JO2334B1 (en) * 2000-01-18 2006-06-28 باير شيرنغ فارما اكتنجيسيلشافت Drospirenone for hormone replacement therapy
US20050215535A1 (en) * 2004-03-24 2005-09-29 Kristof Chwalisz Sequential SPRM/progestin treatment
WO2007103510A2 (en) * 2006-03-08 2007-09-13 Danco Laboratories Llc Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
US20080214512A1 (en) * 2007-03-01 2008-09-04 Christian Seitz Pharmaceutical preparation containing a gestagen, and kit and method for treating endometriosis using the preparation
EP1977752A1 (de) * 2007-03-01 2008-10-08 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zubereitung zur Verminderung der Endometriose
ES2575554T3 (es) * 2007-04-20 2016-06-29 Preglem S.A. Moduladores selectivos de progesterona en el tratamiento de la hemorragia uterina
US20080306034A1 (en) * 2007-06-11 2008-12-11 Juneau Biosciences, Llc Method of Administering a Therapeutic
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
EP2123279A1 (de) * 2008-05-14 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Sequentielle Verabreichung von 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on und einem oder mehreren Gestagenen zur Behandlung gynäkologischer Erkrankungen
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102011004899A1 (de) 2011-03-01 2012-09-06 Bayer Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
WO2012121767A1 (en) * 2011-03-09 2012-09-13 Arstat, Inc. Treatment of uterine fibroids by intravaginal administration of a low dose of selective progesterone receptor modulator (sprm), anti-progestin, or anti-progestational agent
US10328022B2 (en) 2012-05-31 2019-06-25 Repros Therapeutics Inc. Formulations and methods for vaginal delivery of antiprogestins
WO2014070517A1 (en) 2012-11-02 2014-05-08 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
PT2983671T (pt) 2013-04-11 2019-02-25 Bayer Pharma AG Forma farmacêutica de antagonista de recetor de progesterona
US9096641B2 (en) * 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
US9603856B2 (en) * 2013-11-03 2017-03-28 Flamina Holding Ag Pharmaceutical composition or group of compositions for inhibiting autocrine HCG production in adult human cells
FR3078952B1 (fr) * 2018-03-16 2020-03-27 Arianegroup Sas Systeme de mise en orbite de travail pour un satellite

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3733478A1 (de) * 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore

Also Published As

Publication number Publication date
PT772441E (pt) 2002-08-30
EP0772441B1 (de) 2002-02-20
DK0772441T3 (da) 2002-05-27
CN1154067A (zh) 1997-07-09
US6043234A (en) 2000-03-28
AU3254395A (en) 1996-02-22
IS4407A (is) 1997-01-02
MX9700309A (es) 1997-05-31
WO1996003130A1 (de) 1996-02-08
NZ291417A (en) 1998-12-23
DE4426601A1 (de) 1996-02-01
FI970260A0 (fi) 1997-01-22
KR100365879B1 (ko) 2003-03-10
EP0772441A1 (de) 1997-05-14
KR970704450A (ko) 1997-09-06
CN1124848C (zh) 2003-10-22
NO970309D0 (no) 1997-01-24
ES2172592T3 (es) 2002-10-01
ATE213417T1 (de) 2002-03-15
NO970309L (no) 1997-01-24
CA2195425A1 (en) 1996-02-08
FI970260A (fi) 1997-01-22
CA2195425C (en) 2008-03-11
HU226453B1 (en) 2008-12-29
DE59510069D1 (de) 2002-03-28
AU705618B2 (en) 1999-05-27
CZ20797A3 (en) 1997-05-14
PL318264A1 (en) 1997-05-26
JPH10502092A (ja) 1998-02-24
CZ292177B6 (cs) 2003-08-13
HUT77092A (hu) 1998-03-02

Similar Documents

Publication Publication Date Title
US6225297B1 (en) Combination contraceptive
SK10497A3 (en) Use of a progesterone antagonist and of a gestagen for the treatment of endometriosis or leiomyomata uteri
EP0792152B1 (en) Methods of contraception
US5719136A (en) Combination of progesterone antagonists and antiestrogens with partial agonistic action for hormone substitution therapy for perimenopausal and postmenopausal women
RU2189819C2 (ru) Схемы приема прогестогена-антипрогестогена
AU710819B2 (en) Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
SK104995A3 (en) Pharmaceutical hormonal agent and its use
US6506390B2 (en) Progestogen-anti-progestogen regimens
US6143754A (en) Competitive progesterone antagonist for demand-oriented female birth control
US20010016578A1 (en) Compositions and methods for contraception and for treatment of benign gynecological disorders
US20050064031A1 (en) Combination contraceptive, kits that contain the latter, and a method that uses the latter
SK2972002A3 (en) Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt)